M5049 high dose + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis
Conditions
Dermatomyositis, Polymyositis
Trial Timeline
Jan 19, 2023 → Jun 25, 2025
NCT ID
NCT05650567About M5049 high dose + Placebo
M5049 high dose + Placebo is a phase 2 stage product being developed by Merck for Dermatomyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05650567. Target conditions include Dermatomyositis, Polymyositis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05650567 | Phase 2 | Terminated |
Competing Products
14 competing products in Dermatomyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| BAF312 + Placebo | Novartis | Phase 2 | 52 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 32 |
| Etanercept + Placebo | Amgen | Phase 1 | 32 |
| Dazukibart | Pfizer | Phase 3 | 76 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 51 |
| PF-06823859 low + Placebo Arm + PF-06823859 high | Pfizer | Phase 2 | 51 |
| Tofacitinib | Pfizer | Phase 1 | 32 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 51 |
| human immunoglobulin G + Placebo | CSL | Phase 3 | 76 |
| Empasiprubart IV | Argenx | Phase 2 | 49 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 47 |
| Lenabasum 20 mg + Lenabasum 5 mg + Placebo | Corbus Pharmaceuticals | Phase 3 | 69 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 44 |